A double-blind, placebo-controlled trial of topiramate for pathological gambling

World Journal of Biological Psychiatry

Volumn 14, Issue 2, 2013, Pages 121-128

  Berlin, Heather A ^a   Braun, Ashley ^a   Simeon, Daphne ^a   Koran, Lorrin M ^b   Potenza, Marc N ^c   McElroy, Susan L ^d   Fong, Timothy ^e   Pallanti, Stefano ^a   Hollander, Eric ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Impulse control disorder; Impulsivity; Pathological gambling; Placebo controlled; Topiramate

Indexed keywords

PLACEBO; TOPIRAMATE;

ADULT; ARTICLE; BARRATT IMPULSIVENESS SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; IMPULSIVENESS; MALE; NAUSEA; PATHOLOGICAL GAMBLING; SHOULDER PAIN; TREATMENT DURATION; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; FRUCTOSE; GAMBLING; HUMANS; IMPULSIVE BEHAVIOR; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84874890135     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2011.560964     Document Type: Article

References (73)

1. Barratt ES, Patton JH. 1983. Impulsivity: Cognitive, behavioural, and psychophysiological correlate. In: Zuckerman M, editor. Biological basis of sensation seeking, impulsivity, and anxiety. Hillside, NJ: Lawrence Erlbaum Associates. p 77-122.
2. Berlin HA. 2008. Antiepileptic drugs for the treatment of impulsivity. Curr Psychiatry Rev 4: 114-136.
3. Berlin HA, Rolls ET, Kischka U. 2004. Impulsivity, time perception, emotion and reinforcement sensitivity in patients with orbitofrontal cortex lesions. Brain 127(Pt 5): 1108-1126. (Pubitemid 38623046)
4. Berlin HA, Rolls ET, Iversen SD. 2005. Borderline personality disorder, impulsivity, and the orbitofrontal cortex. Am J Psychiatry 162: 2360-2373. (Pubitemid 41740216)
5. Blanco C, Petkova E, Ibanez A, Saiz-Ruiz J. 2002. A pilot placebocontrolled study of fl uvoxamine for pathological gambling. Ann Clin Psychiatry 14: 9-15. (Pubitemid 34538827)
6. Blanco C, Potenza MN, Kim SW, Ibanez A, Zaninelli R, Saiz-Ruiz J, Grant JE. 2009. A pilot study of impulsivity and compulsivity in pathological gambling. Psychiatry Res 167(1-2): 161-168.
7. Brewer JA, Potenza MN. 2008. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75: 63-75. (Pubitemid 350235392)
8. Carter WP, Hudson JI, Lalonde JK, Pindyck L, McElroy SL, Pope HG Jr. 2003. Pharmacologic treatment of binge eating disorder. Int J Eat Disord 34(Suppl): S74-88. (Pubitemid 36935715)
9. Cunningham-Williams RM, Grucza RA, Cottler LB, Womack SB, Books SJ, Przybeck TR, et al. 2005. Prevalence and predictors of pathological gambling: results from the St. Louis personality, health and lifestyle (SLPHL) study. J Psychiatr Res 39: 377-390. (Pubitemid 40404087)
10. Cunningham-Williams RM, Abdallah AB, Callahan C, Cottler L. 2007. Problem gambling and violence among communityrecruited female substance abusers. Psychol Addict Behav 21: 239-243. (Pubitemid 47445184)
11. Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. 2005. Topiramate versus fl uvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 28: 6-10. (Pubitemid 40269711)
12. Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 2007. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 27: 620-624. (Pubitemid 351339450)
13. Dickson-Swift VA, James EL, Kippin S. 2005. The experience of living with a problem gambler: spouse and partners speak out. J Gambl Issues 13: 1-22.
14. Evenden J. 1999a. Impulsivity: a discussion of clinical and experimental fi ndings. J Psychopharmacol 13: 180-192. (Pubitemid 29276830)
15. Evenden JL. 1999b. Varieties of impulsivity. Psychopharmacology (Berlin) 146: 348-361. (Pubitemid 29513276)
16. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A, et al. 2010. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 35: 591-604.
17. First MB, Spitzer RL, Gibbon MG, Williams JBW. 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P, 11/2002 revision). New York, NY: Biometrics Research Department, New York State Psychiatric Institute.
18. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. 2008. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 89: 298-303.
19. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. 1989a. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016. (Pubitemid 19278230)
20. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. 1989b. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006-1011. (Pubitemid 19278229)
21. Goudriaan AE, Oosterlaan J, de Beurs E, Van den Brink W. 2004. Pathological gambling: a comprehensive review of biobehavioral fi ndings. Neurosci Biobehav Rev 28: 123-141. (Pubitemid 38692361)
22. Grant JE, Kim SW, Potenza MN, Blanco C, Ibanez A, Stevens L, et al. 2003. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 18: 243-249. (Pubitemid 36871876)
23. Grant JE, Steinberg MA, Kim SW, Rounsaville BJ, Potenza MN. 2004. Preliminary validity and reliability testing of a structured clinical interview for pathological gambling. Psychiatry Res 128: 79-88. (Pubitemid 39265485)
24. Grant JE, Brewer JA, Potenza MN. 2006. The neurobiology of substance and behavioral addictions. CNS Spectr 11: 924-930. (Pubitemid 46025638)
25. Grant JE, Kim SW, Hartman BK. 2008. A double-blind, placebocontrolled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 69: 783-789. (Pubitemid 351838687)
26. Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. 2010. A Multi-center double-blind, placebo-controlled study of the opioid antagonist nalmefene in the treatment of pathological gambling. Br J Psychiatry 197: 330-331.
27. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Health, Psychopharmacology Research Branch.
28. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
29. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
30. Harvey PD, Greenberg BR, Serper MR. 1989. The affective lability scales: development, reliability, and validity. J Clin Psychol 45: 786-793. (Pubitemid 19271464)
31. Hollander E, Berlin HA. 2008. Impulse-control disorders measures. In: Rush A, First, MB, Blacker, D, editors. Handbook of psychiatric measures. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc. p 667-686.
32. Hollander E, DeCaria CM, Mari E, Wong CM, Mosovich S, Grossman R, Begaz T. 1998. Short-term single-blind fl uvoxamine treatment of pathological gambling. Am J Psychiatry 155: 1781-1783. (Pubitemid 28547509)
33. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. 2000. A randomized double-blind fl uvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 47: 813-817. (Pubitemid 30254054)
34. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. 2005. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 162: 137-145. (Pubitemid 40095683)
35. Hollander E, Berlin HA, Stein D. 2008. Impulse-control disorders not elsewhere classifi ed. In: Hales RE, Yudofsky SC, Gabbard GO, editors. American Psychiatric Publishing Texbook of Psychiatry, 5th Ed. Arlington, VA: American Psychiatric Publishing.
36. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, et al. 2003. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 64: 1335-1341. (Pubitemid 37490239)
37. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. 2003. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361: 1677-1685. (Pubitemid 36577440)
38. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. 2004. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61: 905-912. (Pubitemid 39181080)
39. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. 2007. Topiramate for treating alcohol dependence: a randomized controlled trial. J Am Med Assoc 298: 1641-1651. (Pubitemid 47606653)
40. Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O'Brien CP. 2004. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 75: 233-240. (Pubitemid 38993293)
41. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S, et al. 2008. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 11: 425-438. (Pubitemid 351482505)
42. Kessler RC, Hwang I, LaBrie R, Petukhova M, Sampson NA, Winters KC, Shaffer HJ. 2008. DSM-IV pathological gambling in the National Comorbidity Survey Replication. Psychol Med 38: 1351-1360.
43. Kim SW. 1998. Opioid antagonists in the treatment of impulsecontrol disorders. J Clin Psychiatry 59: 159-164. (Pubitemid 28208329)
44. Kim SW, Grant JE. 2001. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 16: 285-289. (Pubitemid 32822448)
45. Kim SW, Grant JE, Adson DE, Shin YC. 2001. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49: 914-921. (Pubitemid 32493813)
46. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. 2002. A double-blind placebo-controlled study of the effi cacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 63: 501-507. (Pubitemid 34680358)
47. Leombruni P, Lavagnino L, Fassino S. 2009. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr Dis Treat 5: 385-392.
48. Lesieur H. 1998. Costs and treatment of pathological gambling. Ann Am Acad Pol Soc Sci 556: 157-171.
49. Lesieur HR, Blume SB. 1987. The South Oaks Gambling Screen (SOGS): a new instrument for the identifi cation of pathological gamblers. Am J Psychiatry 144: 1184-1188. (Pubitemid 17147523)
50. McElroy SL, Keck PE Jr. 2009. Topiramate. In: Schatzberg A, Nemeroff C, editors. The American Psychiatric Publishing Texbook of Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing.
51. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. 2003. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 160: 255-261. (Pubitemid 41110450)
52. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. 2007. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 61: 1039-1048. (Pubitemid 46551975)
53. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. 2008. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 69: 433-440. (Pubitemid 351549397)
54. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. 2002. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 4: 207-213. (Pubitemid 34591247)
55. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389. (Pubitemid 9136500)
56. Muelleman RL, DenOtter T, Wadman MC, Tran TP, Anderson J. 2002. Problem gambling in the partner of the emergency department patient as a risk factor for intimate partner violence. J Emerg Med 23: 307-312. (Pubitemid 35300263)
57. Nicolato R, Romano-Silva MA, Correa H, Salgado JV, Teixeira AL. 2007. Lithium and topiramate association in the treatment of comorbid pathological gambling and bipolar disorder. Aust NZ J Psychiatry 41: 628.
58. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. 2005. Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud 21: 431-443. (Pubitemid 41713089)
59. Patton JH, Stanford MS, Barratt ES. 1995. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51: 768-774. (Pubitemid 26021724)
60. Petry NM. 2007. Gambling and substance use disorders: current status and future directions. Am J Addict 16: 1-9. (Pubitemid 46341012)
61. Petry NM, Stinson FS, Grant BF. 2005. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 66: 564-574. (Pubitemid 40733697)
62. Potenza MN. 2006. Should addictive disorders include nonsubstance-related conditions? Addiction 101(Suppl 1): 142-151. (Pubitemid 44199506)
63. Potenza MN. 2008. Review. The neurobiology of pathological gambling and drug addiction: an overview and new fi ndings. Phil Trans R Soc London B Biol Sci 363: 3181-3189.
64. Potenza MN. 2009. Non-substance and substance addictions. Addiction 104: 1016-1017.
65. Reis AD, Castro LA, Faria R, Laranjeira R. 2008. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 30: 132-135. (Pubitemid 351955879)
66. Saiz-Ruiz J, Blanco C, Ibanez A, Masramon X, Gomez MM, Madrigal M, Diez T. 2005. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 66: 28-33.
67. Sheehan DV. 1983. The anxiety disease. New York: Charles Scribner & Sons.
68. Shinn AK, Greenfi eld SF. 2010. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 71: 634-648.
69. Sood ED, Pallanti S, Hollander E. 2003. Diagnosis and treatment of pathologic gambling. Curr Psychiatry Rep 5: 9-15. (Pubitemid 38899197)
70. Thurstone L. 1953. Examiner manual for the Thurstone Temperament Schedule. Chicago, IL: Science Research Associates.
71. Volkow ND, Fowler JS. 2000. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 10: 318-325. (Pubitemid 30159298)
72. Wareham JD, Potenza MN. 2010. Pathological gambling and substance use disorders. Am J Drug Alcohol Abuse 36: 242-247.
73. Young RC, Biggs JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-35. (Pubitemid 9006756)